Optinose is a specialty pharmaceutical company focused on creating and bringing to market innovative products for patients with diseases treated by ear, nose, and throat (ENT) and allergy specialists. Our mission is to improve the quality of life for patients. We are working to accomplish that by becoming the leading specialty healthcare company dedicated to creating innovative products that become standard of care for diseases cared for directly by, or in consultation with, ENT and allergy specialists. Our first product for these patients uses one of our patented Bi-Directional⢠Exhalation Delivery Systems (EDS) to uniquely deliver a potent steroid deep into the nose where inflammation can be hard to reach. Our EDS technology has other applications, such as in treatment of neurological or psychiatric disorders. Although these areas are not our focus, we have already successfully developed and out-licensed one product in that space, and plan to partner with organizations who focus on central nervous system treatments to develop more. Source
No articles found.
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
We are a clinical-stage biopharmaceutical company focused on developing and provid...
We are a clinical-stage biopharmaceutical compa...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Bounty0x is a decentralized bounty hunting platform enabling anyone to manage boun...
Bounty0x is a decentralized bounty hunting plat...
Join the National Investor Network and get the latest information with your interests in mind.